Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 13-22

  Gibb, Randall K ^a   Taylor, Douglas D ^a   Tina, Wan ^a   O'Connor, Dennis M ^a,b   Doering, David L ^a   Gerçel Taylor, Çiçek ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA FRAGMENT; GENE PRODUCT; PACLITAXEL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CHEMOSENSITIVITY; CYTOTOXICITY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LD 50; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031127927     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4637     Document Type: Article

References (30)

1. 1. Stewart BW: Mechanisms of apoptosis: Integration of genetic, biochemical and cellular indicators. J Natl Cancer Inst 86:1286-1295, 1994
2. 2. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 341:1251-1254, 1993
3. 3. Schwartzmann RA, Cidlowski JA: Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocrine Rev 14(2):133-151, 1993
4. 4. Ueda N, Shah SV: Apoptosis. J Lab Clin Med 124:169-177, 1994
5. 5. Kerr JF, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73(8):2013-2026, 1994
6. 6. Wyllie AH, Kerr JF, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306, 1980
7. 7. Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82(9):749-755, 1990
8. 8. Demarcq, C, Bunch RT, Creswell D, Eastman A: The role of cell cycle progression in cisplatin-induced apoptosis in chinese hamster ovary cells. Cell Growth Differ 5:983-993, 1994
9. 9. Donaldson KL, Goolsby GL, Wahl AF: Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847-855, 1994
10. 10. Meyn, RE, Stephens LC, Hunter NR, Milas L: Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int J Cancer 60:725-729, 1995
11. 11. Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A: Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85(6):1007-1010, 1995
12. 12. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR: cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463-471, 1996
13. 13. McGuire WP, Hoskins WJ, Brady MF, et al: For the Gynecologic Oncology Group (GOG). A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/paclitaxel (PT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 12:42, 1993
14. 14. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and paclitaxel in human ocarian carcinoma cells in vitro. Br J Cancer 69:299-306, 1994
15. 15. Vanhoefer U, Harstick H, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A:92-97, 1995
16. 16. Owens K, Gercel-Taylor C, Taylor DD, Day TJ, Doering DL: Isolation and characterization of an ovarian carcinoma cell line as a model for drug resistance. Proc Am Assoc Cancer Res 34:26, 1993
17. 17. Burton K: A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315-323, 1956
18. 18. Burton K: Determination of DNA concentration with diphenylamine. Methods Enzymol 12B:163-167, 1968
19. 19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279, 1991
20. 20. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. New Engl J Med 329:1318-1327, 1993
21. 21. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991
22. 22. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
23. 23. Nigro JM, Baker SJ, Preisinger AC: Mutations in the p53 gene product occur in diverse human tumor types. Nature 342:705-708, 1989
24. 24. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci, USA 90:4961-4965, 1993
25. 25. Kohler MF, Kerns BM, Humphrey PA, Marks JR, Bast RC, Berchuck A: Mutation and overexpression of p53 in early-stage ovarian cancer. Obstet Gynecol 81(5):643-650, 1993
26. 26. Katson MB, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1994
27. 27. Lowe SW, Ruley HE, Jacks T, Housmann DE: p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
28. 28. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesck B, Kaye S: Increased accumulation of p53 protein in cisplatin-resistant ovarian cancer cell lines. Int J Cancer 55:678-684, 1993
29. 29. Yaginuma Y, Westphal H: Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52:4196-4199, 1992
30. 30. Fisher D: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994